Sector ETFs — End-of-Day Verdict
1 ACQUIRE + 1 QUEUED, 0 DISPOSE. BUY 217 XBI @ at the 2026-08-10 open, stop, of (68.3%); and QUEUE a GTC buy-limit 265 AIQ @, stop, expiring 2026-08-12. THE PENDING IBB ORDER DID NOT FILL AND THE GUARD IS WHY: July payrolls printed -23,000 against +80,000 expected, September hike odds fell from 55% to 40%, IBB opened at = +1.65% and OUTSIDE the card's -band, so the order was held for re-validation rather than filled blind. The honest cost is (a fill would have been at the open, not the close), and IBB's conviction then fell from below the floor -- the re-validation would have declined it anyway. THE BOOK BUYS THE SAME THESIS THROUGH A BETTER VEHICLE: XBI prints STRONG BUY conv 85, Buy_Rank 1, the only Mostly_Aligned row on the board, adj 81 after the live SE-1 -4 haircut -- 22 points above IBB. Its forward ladder ascends (Est_1W 157.56 / Est_4W 157.99 / Est_12W 162.29, all above the entry, SE-2 does not fire), it is not extended (Entry_Distance_ATR 0.0, RSI 60.2, 5% below its 52W high), and R:R is 3.41:1. NEWS CONFIRMS WITH A DATED MECHANISM: the NFP miss repriced the rate path, and biotech is the sector that responds most directly -- 'the rate-cut trade in disguise', currently the deepest pocket of Nasdaq leadership (~30% of leadership-screen stocks are biotech or healthcare), on decade-high M&A, 46 FDA approvals in 2025, at 24.4x forward vs the market's 27.8x. WEAKNESS STATED: the stop is exactly the session low, ninth such construction in nine sessions, in a family that stops out first 70% of the time; and the buy is a 30-point one-session flip out of AVOID -- fresh, not stable. DECLINES: GLD (adj 72, second-highest) broke out for real on gold +2.7% but risks 8.06% / 3.11 ATR for a +2.68% 12wk view = 0.33:1, and its buy-stop prints 1.55% BELOW the market; QQQ (adj 64) misses the floor by ONE point with otherwise the board's second-best geometry (3.77:1 at 12wk) and is armed at raw 69; XLK (adj 65) became the FIRST row in this book's history to satisfy the ADR-0012 anticipate-slot rule ( prints) and clear the floor, and was killed purely by geometry -- 8.41% / exactly 3.00 ATR of risk for a +3.31% 12wk best case and a NEGATIVE 1wk, in the 0-for-5 family; IWM (raw 83, the board's highest) is slot-ineligible at and risks 4.24% for +0.47%; XLI, UFO, IBB and MAGS are below the floor. SKYY is not a near-miss but a warning: the day's biggest gainer (+3.71%) printed ReversalDown_Overbought at conviction 86, RSI 72.9, AT its 52W high and +10.18% above VWAP -- the most extended row on the board, and long-only means no action. DISPOSE: nothing -- the book is flat, monitor clean, no stops to carry. THE LIVE THREAT TO BOTH CARDS IS THE SAME ONE: July CPI, Wednesday 2026-08-12, 8:30am ET, which decides whether Friday's rate repricing survives.
Recommendations
2 to acquire · 0 to dispose
| Ticker | Name | Close | Action | Action Price Where to act — a buy-limit on a pullback or a buy-stop above resistance, not the current price. Sanity-check vs Close: on a held name, an action price stranded above the close means the queued level was set when the stock was higher — stale, awaiting reprice. | Stop The risk-defined exit, set below the entry for a long (~1.2–1.8×ATR). A held long whose Stop sits at/above the Close is already below its stop — a stale box awaiting reprice. | 1wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. | 4wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. | 12wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. | Rationale |
|---|---|---|---|---|---|---|---|---|---|
| XBI | SPDR S&P Biotech ETF | 157.37 | BUY | 157.37 | 154.96 | 157.56 (+0.1%) | 157.99 (+0.4%) | 162.29 (+3.1%) | Buying small-cap biotech because a weak jobs report has just repriced the path of interest rates, and biotech is the sector that responds most directly to that. July payrolls showed the US economy LOST 23,000 jobs against an expected gain of 80,000, which cut the market's odds of a September rate rise from 55% to 40% -- and biotech, being capital-hungry and long-dated, is in effect the rate-cut trade in disguise. It is already the deepest pocket of leadership in the whole Nasdaq, with roughly 30% of the market's strongest stocks being biotech or healthcare names. Underneath the rate story the fundamentals support it: takeover activity is at decade highs as large drugmakers face patent expiries, 46 new drugs were approved last year, and the sector trades at 24.4 times forward earnings against the wider market's 27.8 while growing faster. This particular fund is the equal-weighted, smaller-company version, which gives more takeover exposure and more rate sensitivity than its large-cap sibling. It is buyable at today's close rather than at a stretched price and sits 5% below its one-year high. The honest caveat: the protective stop is placed at today's exact low, so an ordinary quiet session would close the trade for about a 1.5% loss, and the return is a three-month story while the risk resolves within hours. OPS: STRONG BUY conv 85, Buy_Rank 1, highest print on the board; SE-1 live bias -4 gives adj 81, clears the 65 floor by 16. ONLY Mostly_Aligned row on the board (Trend 78 / Momentum 67 / Volatility 39); every other bullish print is the weaker Consolidation_Bullish. STABILITY CAVEAT: trail AVOID65, AVOID65, AVOID55, SB85 is a 30-point one-session flip out of AVOID -- a FRESH signal, not a stable multi-snapshot one; permitted by the ACT-NOW bar and supported by a real mechanism (the NFP repricing) rather than a label wobble. Market entry, Entry_Distance_ATR 0.0, RSI 60.2, 5.03% below the 165.71 52W high, above EMA20/50/200 and VWAP. SIZING: 85.49% x x 20% =, size_mod 1.0 (valuation blind), max_position_pct cap not binding, not binding on this card alone, giving = = 68.3% of declared, leaving. STOP = -1.53% = 0.586 ATR and is EXACTLY the printed session low -- the NINTH stop-at-the-session-low in nine sessions (systemic finding 1), in the family whose stop_first_rate is 0.70. Better constructed than the IBB cards it replaces (0.586 ATR vs 0.50) and R:R = 8.23/2.41 = 3.41:1. GATE: clears at 12wk only (+3.13% vs a 1.53% stop = 2.04:1); Est_1W +0.12% and Est_4W +0.39% are flat. SE-2 does NOT fire (162.29 above 157.99 above 157.37), third straight session that the chosen acquire is the only ascending-ladder row on the board. Est_* read directly per ADR-0013 (~80% bands: 1W 150.84-165.54, 4W 150.23-171.42, 12W 141.47-189.28); calib_1w -0.068 degenerate so the 1wk figure carries a low-reliability flag per SE-3/L5. THESIS CONTINUITY: this is the same healthcare/biotech idea the book tried to express via IBB on 07-30 and 08-06, now in the vehicle that prints 22 points more conviction (85 vs 63). L8: execute at the 2026-08-10 open; REPRICE AND RE-VALIDATE if the open gaps more than 1.5% (outside -). HORIZON THREAT: July CPI Wed 08-12 8:30am ET is the event that decides whether the rate repricing this trade rests on survives. ADR-0019: BOTH the 07-30 IBB card (6th session) and the 08-06 IBB card remain unrecorded -- 'trade buy' or 'trade skip sectoretf IBB' for each. · news |
| AIQ | Global X AI & Tech ETF | 63.35 | BUY — QUEUED @59.64 | 59.64 | 57.58 | 63.41 (+6.3%) | 63.34 (+6.2%) | 65.53 (+9.9%) | A standing order to buy the AI and technology fund only if it falls back roughly 6% from where it closed. The fund is genuinely well placed -- technology rose 1.3% on Friday and 5% over the week as a weak jobs report pushed back the prospect of higher interest rates -- but the book will not pay Friday's price for it. The order sits below the fund's recent average price, is protected by a stop with real room beneath it rather than one perched at the day's low, and if it fills the system's own forecasts point about 6% higher at one and four weeks and 10% higher at three months. It should be said plainly that this order will probably not fill: a 6% pullback in a fund that just rose on good news is not the likely outcome, and the book's last three below-market orders of this kind all expired unfilled. It costs nothing to leave it working, and it expires automatically in three sessions. OPS: BUY conv 67, Buy_Rank 4, PullbackBuy_VWAP -- the L1-favoured family; the cell is ACTIONABLE at n=6 hit_1w 0.5 with bias +0, so NO haircut, adj 67, clears the floor by 2. Buy Limit @59.64 vs a 63.35 close = 5.86% / 2.09 ATR below market (Entry_Distance_ATR -2.09). SIZING -- -CAPPED: model 49.24% x x 20% = =, but the XBI acquire consumes of the leaving, so the order is cut to = (-19.7%). If both fill the book is 99.9% and no third acquire is possible -- which is independently why UFO and QQQ could not be added even had they cleared. STOP = -3.45% from the limit = 1.16 ATR -- the ONLY card in weeks with a real stop rather than a session-low pin; R:R = 4.12/2.06 = 2.00:1 vs Target_Price 63.76. GATE CLEARS AT ALL THREE TENORS, the only card on the board of which that is true: Est_1W 63.41 (+6.32%), Est_4W 63.34 (+6.20%), Est_12W 65.53 (+9.88%) vs a 3.45% stop = 2.86:1 at 12wk, 1.83:1 even at 1wk. READ IT HONESTLY: the Est_* are computed off the 63.35 close, so the +6% is the size of the discount the limit asks for, not a forecast rally -- the model's actual view is that AIQ stays put; the trade is 'buy it 5.9% cheaper if offered'. FILL EXPECTATION LOW: XLF precedent is three consecutive unfilled below-market limits before that signal collapsed to zero. ADV-1 applies -- no_chase_queue counterfactual n=16 median withheld-1w +0.67%, approximately neutral; this is execution hygiene, not an edge. expires_on 2026-08-12 = anchor plus 3 trading sessions (08-10, 08-11, 08-12). COLLISION: the limit expires ON CPI day -- if CPI runs hot and AIQ sells into the limit, RE-VALIDATE against the live row before accepting the fill; a CPI-driven fill is a shock, not a clean pullback. · news |
| IBB | iShares Biotech ETF | 197.71 | WATCH | 197.54 | 185.07 | 197.87 (+0.2%) | 199.35 (+0.9%) | 204.42 (+3.5%) | Thursday's order to buy biotech was not executed, and it was not executed because the order's own safety condition stopped it. The card was written to be placed at Friday's opening bell unless the market opened more than 1.5% away from the reference price. The jobs report landed an hour before the open, the fund opened 1.65% higher, and the condition therefore required the order to be re-checked rather than filled blind. Nobody was available to re-check it, so the book stayed flat. The cost of that is smaller than it appears -- the fill would have happened at the opening price, not the closing price, so the miss is about 0.8% or not 2.5% -- and the re-check would in any case have declined the trade, because the fund's rating fell 12 points on the day and is now below the book's minimum. A safety condition that costs and prevents a blind purchase into a collapsing rating is a condition working correctly. The same underlying idea has instead been bought today through the small-cap biotech fund, which rates 22 points higher. OPS: ADR-0019 UNRECONCILED. 08-06 card was BUY 102 @192.97 market, execute_on 2026-08-07, stop 191.08, band -; NFP printed -23k vs +80k expected at 8:30am ET; IBB OPENED 196.15 = +1.65%, OUTSIDE the band, so held for reprice/re-validation; run unattended, no discretionary reprice, book still flat. Counterfactual: fill at the 196.15 open gives +0.80% by the 197.71 close = on (NOT the +2.46% the closing price implies). TODAY: conv (-12), family rotated FailedBreakdown_Up_20D to BreakoutUp_52W, adj 63 BELOW the 65 floor -- the re-validation would have declined it. Buy Stop @197.54 prints 0.09% BELOW the 197.71 close (systemic finding 3); stop 185.07 = 12.47 = 6.31% = 3.11 ATR, a completely different construction from the 0.50-ATR stop the same ticker carried two sessions ago. RESOLVE BOTH IBB CARDS: the 07-30 card (BUY 65 @189.96, stopped out on its execution session, about -if taken) is now SIXTH-session unrecorded, and the 08-06 card joins it. 'trade buy' or 'trade skip sectoretf IBB' for each. Portfolio JSON shows and trades_detected is empty. · news |
Outcome & track record